Gilead Sciences: COVID-19 trials

The registry lists 10 COVID-19 studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 1Phase 2 3Phase 3 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Obeldesivir in Children and Adolescents With COVID-19TerminatedNCT05996744Phase 2/3Results posted
• Study of Obeldesivir in Nonhospitalized Participants With COVID-19CompletedNCT05715528Phase 3Results posted
• Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe IllnessTerminatedNCT05603143Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)TerminatedNCT04745351Phase 3Results posted
• Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by InhalationCompletedNCT04539262Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient SettingTerminatedNCT04501952Phase 3Results posted
• Study of Remdesivir in Participants Below 18 Years Old With COVID-19CompletedNCT04431453Phase 2/3Results posted
• Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)CompletedNCT04292899Phase 3Results posted
• Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care TreatmentCompletedNCT04292730Phase 3Results posted
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)Approved for marketingNCT04323761